196 related articles for article (PubMed ID: 32447461)
21. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.
de Baere T; Deschamps F; Tselikas L; Ducreux M; Planchard D; Pearson E; Berdelou A; Leboulleux S; Elias D; Baudin E
Eur J Endocrinol; 2015 Apr; 172(4):R151-66. PubMed ID: 25385817
[TBL] [Abstract][Full Text] [Related]
22. Histologically-Proven Efficacy of Bland Embolization in a Patient with Net Liver Metastasis.
Monfardini L; Varano GM; Foà R; Della Vigna P; Bonomo G; Bertani E; Guerini-Rocco E; Spada F; Orsi F
Cardiovasc Intervent Radiol; 2016 Jun; 39(6):948-52. PubMed ID: 26714693
[TBL] [Abstract][Full Text] [Related]
23. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
[TBL] [Abstract][Full Text] [Related]
24. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
[TBL] [Abstract][Full Text] [Related]
25. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness.
Xing M; Kokabi N; Camacho JC; Kooby DA; El-Rayes BF; Kim HS
J Comp Eff Res; 2013 Jul; 2(4):435-44. PubMed ID: 24236684
[TBL] [Abstract][Full Text] [Related]
26. Radioembolization Versus Chemoembolization for Neuroendocrine Metastases.
Padia SA
J Vasc Interv Radiol; 2021 Mar; 32(3):482-483. PubMed ID: 33376030
[No Abstract] [Full Text] [Related]
27. The Landmark Series: Neuroendocrine Tumor Liver Metastases.
Gangi A; Howe JR
Ann Surg Oncol; 2020 Sep; 27(9):3270-3280. PubMed ID: 32632880
[TBL] [Abstract][Full Text] [Related]
28. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
[TBL] [Abstract][Full Text] [Related]
29. Hepatic neuroendocrine metastases: chemo- or bland embolization?
Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
[TBL] [Abstract][Full Text] [Related]
30. Treatment options for unresectable neuroendocrine liver metastases.
John BJ; Davidson BR
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):357-69. PubMed ID: 22646257
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and complications of treating neuroendocrine metastases, embolization versus chemoembolization.
Hartnell GG
J Vasc Interv Radiol; 1999; 10(10):1416-7. PubMed ID: 10584661
[No Abstract] [Full Text] [Related]
32. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
Salman HS; Cynamon J; Jagust M; Bakal C; Rozenblit A; Kaleya R; Negassa A; Wadler S
Clin Colorectal Cancer; 2002 Nov; 2(3):173-9. PubMed ID: 12482334
[TBL] [Abstract][Full Text] [Related]
33. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).
Hoffmann RT; Paprottka P; Jakobs TF; Trumm CG; Reiser MF
Abdom Imaging; 2011 Dec; 36(6):671-6. PubMed ID: 21584635
[TBL] [Abstract][Full Text] [Related]
34. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
[TBL] [Abstract][Full Text] [Related]
35. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
[TBL] [Abstract][Full Text] [Related]
36. Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization
Chang J; Charalel R; Noda C; Ramaswamy R; Kim SK; Darcy M; Foltz G; Akinwande O
Anticancer Res; 2018 May; 38(5):3063-3068. PubMed ID: 29715141
[TBL] [Abstract][Full Text] [Related]
37. Developments in interventional management of hepatic metastases from neuroendocrine tumours.
Clift AK; Thomas R; Frilling A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101798. PubMed ID: 37468404
[TBL] [Abstract][Full Text] [Related]
38. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
[TBL] [Abstract][Full Text] [Related]
39. Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?
Sangha BS; Nimeiri H; Hickey R; Salem R; Lewandowski RJ
Curr Treat Options Oncol; 2016 Jun; 17(6):26. PubMed ID: 27098532
[TBL] [Abstract][Full Text] [Related]
40. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution.
Engelman ES; Leon-Ferre R; Naraev BG; Sharma N; Sun S; O'Dorisio TM; Howe J; Button A; Zamba G; Halfdanarson TR
Pancreas; 2014 Mar; 43(2):219-25. PubMed ID: 24518499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
